Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see how well the medication Alefacept (Amevive®)
works for continuous treatment of chronic plaque psoriasis. The US Food and Drug
Administration (FDA) has approved Alefacept in an intermittent dosage schedule of 15 mg
weekly injection for 12 weeks followed by 12 weeks off treatment.